BASEL, Switzerland – Roche has received CE Mark for its Accu-Chek Solo micropump system, a tube-free insulin delivery system that offers users the choice to bolus directly from the pump or from the fully-functional handheld, as well as to detach and re-attach the pump without wasting insulin. “This important milestone will enable us to further expand access to insulin pump therapy to those people with diabetes who can benefit most from this therapy option—so they can spend more time in their ideal target range and experience an improved quality of life,” said Roland Diggelmann, CEO of Roche Diagnostics, in a statement. The Accu-Chek Solo micropump integrates with Roche’s digital health solutions like the Accu-Check Smart Pix system. The company will initiate the pilot commercialization phase for the system in Austria, Poland, Switzerland and the UK in the coming weeks and is conducting a clinical study in several European countries.
You are here: / / Roche receives CE Mark for tube-free insulin delivery system